Exclusive Summary

• - The 2.5 mg prefilled syringe covers core uses in VTE prophylaxis and NSTE-ACS, is guideline-endorsed and on the WHO EML, ensuring steady demand.
• - Fully synthetic, non–animal-derived and usable in HIT, once-daily with no routine monitoring, offering safety and supply-chain advantages over LMWH.
• - Patents expired years ago; US/EU are genericized but technical barriers keep high-quality suppliers limited, leaving room in emerging-market tenders.
• - USP-grade API plus Distribution/Technology Transfer enable faster registration and local manufacturing (Vietnam requires direct/local partner).
• - Versus originator, typical 30–60% price cuts are achievable; the high-volume 2.5 mg SKU supports scale economies for tenders.